Citadel Advisors’s Mural Oncology MURA Stock Holding History

Citadel Advisors’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-258,250	Closed	-$535K	–	13587
2025 Q3	$535K	Buy	258,250 +185,898	+257%	+$400K	﹤0.01%	8967
2025 Q2	$179K	Buy	+72,352	New	+$171K	﹤0.01%	10785
2025 Q1	–	Sell	-98,076	Closed	-$358K	–	15203
2024 Q4	$316K	Buy	98,076 +88,256	+899%	+$311K	﹤0.01%	9551
2024 Q3	$30.7K	Sell	9,820 -12,688	-56%	-$41.3K	﹤0.01%	12408
2024 Q2	$70.7K	Sell	22,508 -35,741	-61%	-$132K	﹤0.01%	11365
2024 Q1	$285K	Sell	58,249 -189,933	-77%	-$922K	﹤0.01%	9561
2023 Q4	$1.47M	Buy	+248,182	New	+$998K	﹤0.01%	5932

Citadel Advisors's MURA Position: Q4 2025 in Review

Citadel Advisors sold out of Mural Oncology (MURA) in Q4 2025, closing a stake of 258,250 shares — an estimated $535K sold.

Citadel Advisors first reported a position in MURA in Q4 2023 and held it in 7 quarters. The position peaked at $1.47M in Q4 2023. 0 funds tracked by Wall St. Rank hold MURA as of Q4 2025.

Citadel Advisors reported no remaining Mural Oncology position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 258,250 Mural Oncology shares in Q4 2025, an estimated $535K.
Citadel Advisors first reported a position in Mural Oncology in Q4 2023 and held it in 7 quarters.
Citadel Advisors's Mural Oncology position peaked at $1.47M in Q4 2023.
0 funds tracked by Wall St. Rank held Mural Oncology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.